earnings
confidence high
sentiment neutral
materiality 0.70
Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B
Jazz Pharmaceuticals plc
2024-Q1 EPS reported
-$0.23
revenue$901,983,000
- Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.
- Non-GAAP adjusted net income $182.2M ($2.68 EPS) down from $285.3M ($3.95 EPS); cost increases in SG&A and R&D.
- Key growth drivers: Xywav +14%, Epidiolex +5%, Rylaze +20% YoY; Xyrem fell 64% to $64.2M.
- Oncology revenues +13% to $257.5M; zanidatamab BLA for 2L BTC submitted; Phase 2b suvecaltamide data expected late 1H24.
- FY24 guidance affirmed: total revenue $4.0-4.2B, non-GAAP gross margin ~93%, non-GAAP EPS $18.15-19.35.